After myeloablative conditioning therapy and hematopoietic stem cell transplantation (HSCT), patients judged oral mucositis as the most debilitating side effect of their therapy [1] . For most myeloablative regimens the incidence of severe mucositis ranges between 30 to 70 % [2] , and may exceed even 95 % for highly toxic regimen [3] . Observational studies demonstrated a strong association between severity of oral mucositis and days with fever, significant infection, need for parenteral nutrition and injectable narcotic therapy, as well as therapy-related mortality [4] .
Palifermin (Kepivance ® , Swedish Orphan Biovitrum), a truncated form of recombinant human keratinocyte growth factor 1, demonstrated its ability to reduce mucositis after chemo-/ irradiation therapy in preclinical models [5] and human studies [6] , and became FDA approved in 2004. The updated Clinical Practice Guidelines by the MASCC/ISOO recommended the use of palifermin only for total body irradiation (TBI)-based autologous HSCT, while no recommendation could be given in the allogeneic setting due to conflicting results and insufficient evidence [7] .
Here we report our results from a prospective, controlled multicenter trial designed to evaluate efficacy and safety of palifermin for prevention of oral mucositis in TBI-based allogeneic HSCT. Patients were randomized in a 2:1 ratio to receive either a mucositis prophylaxis by palifermin or standard supportive care. The trial was designed according to the Declaration of Helsinki, and was approved by the ethics committee of each participating center.
The uniform conditioning regimen consisted of hyperfractionated TBI (total dose 12 Gy) followed by cyclophosphamide (2 × 60 mg/kg). A cell count of 4.0 × 10 6 CD34-positive peripheral blood stem cells per kg bodyweight was requested, and no graft manipulation like cell sorting, T-cell depletion or cryopreservation was performed. Only HLAidentical family donors or unrelated donors with an HLAmatch of at least 8/10 (HLA class I: A,B,C; HLA class II: DR, DQ) were accepted. All patients received cyclosporine (3-5 mg/kg per day) and low-dose methotrexate (MTX, 15 mg/m 2 on day 1 and 10 mg/m 2 on day 3, 6, 11) for prophylaxis of GvHD. Administration of antithymocyte globulin (ATG) was allowed according to the standard institutional practice of each center.
Palifermin was given as intravenous injections according to the approved dosing schedule of 60 µg/kg per day for 3 consecutive days prior to TBI and for 3 further days after HSCT (+6 h, day +2, and day +4). No palifermin was given within 24 h before and 48 h after conditioning therapy, as well as on days of MTX administration. Supportive care was performed according to the institutional standard of each center and was identical for study and control group.
Severity of oral mucositis (≥WHO III°; primary endpoint) was assessed daily from beginning of palifermin administration until day 30 after HSCT by a trained nurse according to the five-grade WHO oral-toxicity scale [8] . Secondary endpoints included days of intravenous opioidcontaining analgesia, total parenteral nutrition, febrile neutropenia (>38.3°C and <0.5 × 10 9 /l polymorphonuclear cells), and therapy-related mortality until day +100 after HSCT. For grading of acute GvHD, the modified system of Glucksberg was applied [9] . Adverse events were assessed according to the NCI CTCAE V.3 criteria.
Statistical analysis (intent-to-treat) was performed using SPlus Software (Insightful Corp., Seattle, WA, USA). For descriptive statistics, mean ± s.d. (range) is reported. Confirmatory testing of the primary endpoint was performed by the Cochran-Mantel-Haenszel method stratified according to study center with a one-sided alpha of 0.05. According to power calculations, a 30% reduction of severe oral mucositis (≥ WHO III°) would be detected with a one-sided alpha of 0.05 and a power of 0.80, if a total of 81 evaluable patients were enclosed in this trial. For testing of intergroup differences at baseline and secondary endpoints, Fisher´s exact test (nominal data) and Wilcoxon test (continuous data) were used, providing two-sided p values. The level of significance was set to p < 0.05.
Even though recruitment phase was extended for more than 1 year to finally 45 months, only a total of 60 evaluable patients could be enrolled into the trial (palifermin N = 40, control group N = 20). Poor recruitment resulted from a common trend towards broader use of reduced-intensity conditioning regimen and enrollment to competing trials. Baseline characteristics of all patients are given in Table 1 . Significant inter-group differences at baseline were only seen for prior cranial irradiation (palifermin) and MDS/ MPN patients (control). All patients received the full dose of 12 Gy TBI, and only 3 patients needed an unplanned individual dose-reduction of cyclophosphamide. The follow-up data for all patients were complete at day+30 after HSCT, and only one patient of the palifermin group got lost for follow-up thereafter due to withdrawal of consent.
All patients in the palifermin group received at least 4 doses of palifermin, and 37 patients completed all 6 applications (Table 1) . Palifermin was generally tolerated well. Most patients experienced a thickening and a white-film coating of the oral mucosa and/or the tongue after the first 3 applications, which was generally mild to moderate and completely resolved before discharge from hospital. However, one patient refused medication after the 4th dose due to massive mucosal swelling and hypersalivation. Two further patients who received all 6 doses also experienced a severe mucosal swelling and were later classified as mucositis WHO IV°because of their inability for any oral intake, even though they had no ulcers. Palifermin had no influence on platelet or neutrophil engraftment as well as relapse incidence 1 year after HSCT. No difference was seen in the relative number of adverse events (10.4 AEs per patient palifermin vs. 11.1 AEs control group; n.s.). Most events were mild to moderate (Grade I or II), and were directly related to the myeloablative regimen. A 10% higher incidence after palifermin was seen for dermal reactions (erythema, pruritus, burn), sensory neuropathy or taste alterations and hyperglycemia (all Grade I or II, completely reversible). Palifermin significantly reduced the relative number of severe adverse events (0.42 SAEs per patient palifermin vs. 0.80 SAEs control; p < 0.05)
The incidence of severe mucositis ≥WHO III°(primary endpoint) decreased from 75% in the control group to 62.5% after administration of palifermin (Fig. 1 ), but failed statistical significance (p = 0.11). All secondary endpoints demonstrated a consensual, but not significant trend towards reduced duration of mucositis, fewer day of parenteral nutrition or opioid-containing analgesia, and a lower incidence of febrile neutropenia. A significant difference (p < 0.05) was only found for therapy-related mortality until day +100. While all palifermin patients survived, 3 patients One dose not given due to a nursing mistake, the reason for the other missed dose was not documented c Death was related to the following: (1) a massive oro-pharyngeal ulceration with consecutive global respiratory insufficiency (ARDS), from the control group had died due to infectious/inflammatory reasons (Table 1) .
Incidence of early onset of acute GvHD (day +30, any grade) was lower in the palifermin group. Significance was reached only when acute GvHD ≥ grade II was analyzed (12,5% palifermin vs. 35% control; p < 0.05). This difference dissolved for the prevalence of acute GvHD at day +100 after HSCT (Table 1) .
After TBI-based myeloablative conditioning and autologous HSCT, Spielberger et al. reported a 35% reduction of mucositis ≥ WHO III°by palifermin [3] . In comparison, the 12.5% reduction, we observed in the allogeneic setting of our trial clearly dropped behind expectations. In accordance to our results, Langer et al. reported a decrease of 16% for mucositis ≥ WHO III°by palifermin after allogeneic HSCT without reaching statistical significance compared to a retrospective control [10] . Significant improvements were seen for duration of mucositis, parenteral nutrition and use of opioid analgesics. Similarly, Goldberg et al. demonstrated that palifermin reduces days with parenteral nutrition, patient-controlled analgesia, and duration of in hospital stay for TBI-based, but not for chemotherapy-based allogeneic HSCT [11] .
After applying a different dosing schedule of palifermin with a single, collapsed dose of 180 µg/kg after completion of conditioning therapy, palifermin may exert an even adverse effect [12] . Therefore, a dose adjustment of palifermin for different therapy regimen had been postulated [13] . Difficulties in allogeneic HSCT arise from interactions with GvHD-directed prophylaxis, especially MTX, since preclinical models reveal that MTX may counteract the protective effect of palifermin [14] . Due to lacking evidence, the optimal dosing schedule of palifermin in allogeneic HSCT is still unknown [15] .
To our knowledge, this is the first prospective trial that investigated the use of palifermin in allogeneic HSCT with a uniform conditioning regimen for study and control group. We are aware of some limitations, as follows: (1) The trial was underpowered to reach statistical significance. (2) The protective effect of palifermin might have been counteracted by an imbalanced allocation of more patients with prior cranial irradiation and less patients with MDS/ MPN to the palifermin arm (less toxic prior therapy). (3) The intended mucosal thickening by palifermin protects from large-scale ulcerations, but enhances functional problems, especially swallowing. These qualitative chances are not assessed by the WHO mucositis scale, which easily overestimates severity of mucositis due to the functional impairment.
In conclusion, palifermin was generally well tolerated and positively influenced severity, duration and clinical management of oral mucositis. However, the clinical benefit fell short of expectations and did not reach statistical significance. Nevertheless, the positive trend was supported by the consensual development of all secondary endpoints, especially therapy-related mortality. The results are encouraging for further research. Especially studies on the optimal dosing schedule are necessary to perform.
